“Juvenile idiopathic arthritis constitutes a significant cause of disability and quality of life impairment in pediatric and adult patients,” investigators stated. “Recent advances in JIA treatment addressing more specific targets have led to better short and long-term disease outcomes."
Factors that impacted poor outcomes in patients with COVID-19 were closely related to age and comorbidities, not rheumatic disease diagnosis. Increased risk was seen in patients receiving glucocorticoids.
The COVID-19 pandemic continues to negatively impact symptom severity, sleep quality, and mood in patients with fibromyalgia.
Results show a significantly higher risk of death and combined poor outcomes compared with patients without lupus and both with and without other comorbidities.
How much do you know about the treatment of patients with rheumatoid arthritis? Find out now with our quiz.
The Epionics SPINE is an innovative tool to assess the spinal mobility of patients with axial spondyloarthritis.
Investigators found that patients who were not treated with biologic medications were at a significantly increased risk of developing psoriatic arthritis.
Investigators set out to determine the effect on social media use in relation to disease severity and sleep quality in patients with fibromyalgia.
The indication granted Monday makes the 2-dose vaccine the very first approved by the FDA for the prescribed prevention of COVID-19.
Test your knowledge with our Rheumatoid Arthritis: 2021 Highlights quiz!
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 20, 2021.
Investigators gathered data from vulnerable populations with rheumatic disease regarding their thoughts and opinions on the COVID-19 virus.
In this retrospective study, investigators analyzed patients with newly diagnosed RA, to determine if short-term, low doses (< 10 mg/day) of prednisone would help DAS28-ESR score.
Research suggests that men and women of all ages in mainland China recorded similar results of untreated osteoporosis and vertebral and clinical fractures, all of which are becoming more prevalent over time.
Anakinra treatment may reduce mortality risk in patients with moderate-to-severe COVID-19, especially for those with hyperinflammation.
The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.
Test your knowledge of rheumatoid arthritis with our "Best of 2020" quiz!
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 13, 2021.
Patients with rheumatic disease reported significant employment status changes, which may imply issues with healthcare access, affordable medication, mental health concerns, and rheumatic disease activity. However, they tended to follow public health advice and continued therapy to mitigate the risk of COVID-19 diagnosis.
Compared with controls, patients with psoriatic arthritis presented more often with depression at baseline and patients with rheumatoid arthritis had a higher incidence of cardiovascular comorbidity after 3 years.
Only 11% of patients reported a flare that required treatment and no participants experienced severe flares. Approximately 60% of flares occurred after D2.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 6, 2021.
Although it is assumed that fatigue is related to inflammation, disease activity, or treatment with drugs such as Methotrexate, it can affect children independent of disease activity and impacted by psychosocial factors.
The risk of developing systemic lupus erythematosus (SLE) was reduced by 19% with every increase in a healthy lifestyle index score (HLIS). The risk of dsDNA positive SLE reduced 22% with the addition of each healthy behavior. Those with genetic risk factors may be able to reduce their risk of SLE diagnosis by almost 50% with adherence to healthy lifestyle behaviors.
Researchers call for greater research on the relationship between PTSD and autoimmune diseases in Medicaid patients after finding a troubling association.
In this Q&A, corresponding author Josef S Smolen, MD, discussed the findings of his study determining the effectiveness of ustekinumab versus tumor necrosis factor inhibition in patients with psoriatic arthritis.
The US Food and Drug Administration (FDA) announced the approval of anifrolumab-fnia (Saphnelo™) for the treatment of moderate to severe systemic lupus erythematosus.
Conversations assessing and responding to suicide risk with your patients destigmatizes suicide and mental illness while strengthening your skills as a provider.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 30, 2021.
